Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 powder is mixed with a 70% ethanol and 30% propylene glycol solution, with some users seeking PG-free alternatives. Minoxidil is also mentioned as a treatment option.

The user is considering using "Grow Gorgeous Intense Hair Density Serum" alongside Minoxidil and is currently taking Finasteride. Some users doubt the serum's effectiveness, while others suggest it may help with hair strength and thickness, but opinions are mixed.

The user reported using 1.1 mg finasteride, 5 mg minoxidil, 1 mg biotin, dermastamping twice a week, and Nizoral shampoo and anti-itch liquid. The replies praised the progress and suggested a follow-up at six months.

Stemoxydine is available in L'Oréal's Serioxyl and Dercos Neogenic products, which can be found on Amazon, Ulta, or L'Oréal's website. A user is selling three bottles of L'Oréal Stemoxydine.

A 27-year-old man with thinning hair saw improvement after stopping Rogaine and starting dermarolling with peppermint oil, experiencing less shedding and thicker hair growth. He also uses biotin caffeine shampoo, argan oil conditioner, and a mix of castor oil with peppermint oil after dermarolling.

The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.

The user has been using Minoxidil for 4 years and recently added a derma pen and Trinov to their regimen, but results are inconclusive after 3 months. Some users suggest Trinov is ineffective and recommend alternatives like Clascoterone (Breezula) for better results.

Parabens in Minoxidil are a concern for some users due to potential health risks. The conversation discusses the presence of methylparaben and propylparaben in a specific Minoxidil brand, Ylox.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

A 21-year-old is using oral minoxidil, rosemary oil, saw palmetto, and pumpkin seed oil for hair regrowth but is advised to use finasteride or dutasteride for better results. The user is hesitant to use DHT blockers due to cost and is seeking advice on whether their current regimen is effective.

The user shared their 3-month progress using 2.5mg oral minoxidil, 0.5mg dutasteride, 5mg biotin, and a saw palmetto, green coffee, and menthol shampoo, reporting no hair shedding and some unwanted hair growth on the beard and back. They recommend starting with finasteride or dutasteride, especially for those under 18, and noted no side effects from their treatment.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

A user reports significant hair shedding and regrowth after increasing their dutasteride dosage to 5mg, alongside using RU58841, minoxidil, and topical finasteride, with no side effects. They recommend high doses of dutasteride, sourced from China, despite concerns about its safety.

The user is seeing progress in hair regrowth using a combination of 8% minoxidil, 0.25% dutasteride, and 0.01% tretinoin. The conversation includes comments on the effectiveness and application of these treatments.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

The user is experiencing prolonged hair shedding despite using Dutasteride, Xpecia, Ocean Capilus, and microneedling. They are considering adding minoxidil due to concerns about the effectiveness of their current regimen.

A 22-year-old male experienced hair regrowth using an intermittent Dutasteride regimen, oral and topical Minoxidil, FolliHair AM/PM, and Salicia KT shampoo. He stopped Dutasteride due to side effects like dry eyes and skin, but noticed increased hair shedding after stopping.

A user shared progress pictures after 50 days of using a compound with 10% minoxidil, 0.1% finasteride, and biotin, expressing satisfaction with the results. Another user commented positively on the progress.

The post discusses a user's successful hair regrowth using finasteride, dutasteride, topical minoxidil, and estrogen over nine months. The user, who is male-to-female (mtf), reports significant regrowth and no side effects beyond typical hormone replacement therapy effects.

The user has been using finasteride for 7 months and is experiencing some regrowth but struggles with an oily scalp despite trying ketoconazole and salicylic acid. They are seeking advice on managing the oily scalp and are reassured by others that regrowth is visible.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The user is using Minoxidil, finasteride, Nizoral, and dermarolling for hair loss but is not seeing results. They are considering trying a product called "capilia longa" for beard growth and are questioning its effectiveness.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

A 54-year-old user shares progress after 3 years on dutasteride, following 15 years on finasteride, using 0.5 mg/day dutasteride, topical minoxidil every other day, and a peptide serum on alternate days. They experienced a significant shed during the transition but are now maintaining hair, noticing some new growth along the hairline.